Blog
RSS FeedPosted by Michael Wonder on 12 Mar 2024
25,000 people to benefit after NICE recommends new ulcerative colitis treatment
11 March 2024 - New one a day pill recommended on the same day the treatment was granted a licence ...
Posted by Michael Wonder on 07 Mar 2024
Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation
28 February 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 06 Mar 2024
Epcoritamab for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma after two or more systemic treatments
6 March 2024 - NICE has published final evidence-based recommendations on the use of epcoritamab (Tepkinly) for the treatment of ...
Posted by Michael Wonder on 06 Mar 2024
NICE publishes final draft guidance on Enhertu after commercial discussions conclude without a price to make it a cost-effective use of NHS resources
6 March 2024 - NICE has published final draft guidance that does not recommend Enhertu (trastuzumab deruxtecan; Daiichi Sankyo) for treating ...
Posted by Michael Wonder on 06 Mar 2024
Updated agenda for March 2024 PBAC meeting (6 March 2024)
6 March 2024 - The agenda for this March 2024 meeting has been updated. ...
Posted by Michael Wonder on 05 Mar 2024
Pembrolizumab in combination with chemotherapy for the treatment of patients with advanced HER2 negative gastric or gastro-oesophageal junction adenocarcinoma
5 March 2024 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...
Posted by Michael Wonder on 05 Mar 2024
New treatment option available today for womb cancer
5 March 2024 - A new treatment option given with chemotherapy is recommended for some types of advanced or recurrent ...
Posted by Michael Wonder on 04 Mar 2024
Findings from the Lean review of our drug reimbursement review program
29 February 2024 - Last year, CADTH communicated several improvements to our drug reimbursement review program, including a Lean review ...
Posted by Michael Wonder on 04 Mar 2024
Together for high standards in the assessment of health technologies in Europe from 2025
1 March 2024 - A few months before the EU HTA regulation came into force, a delegation from the French HTA ...
Posted by Michael Wonder on 04 Mar 2024
Tebentafusp in uveal melanoma: indication of a considerable additional benefit
1 March 2024 - Patients with inoperable or metastatic uveal melanoma survive longer with the new therapy than with other therapy ...
Posted by Michael Wonder on 02 Mar 2024
Patisiran sodium in hereditary transthyretin amyloidosis: less benefit than vutrisiran
1 March 2024 - In 2023, IQWiG found an additional benefit of vutrisiran compared to patisiran sodium based on a study. ...
Posted by Michael Wonder on 01 Mar 2024
Public Summary Documents – November 2023 PBAC meeting (round 1)
1 March 2024 - The Public Summary Documents (positive recommendations and subsequent decisions not to recommend) from the November 2023 PBAC ...
Posted by Michael Wonder on 01 Mar 2024
More rare conditions considered for newborn bloodspot screening and new treatment option for spinal muscular atrophy
29 February 2024 - On Rare Disease Day, the Albanese Government has announced two more rare genetic conditions have been ...
Posted by Michael Wonder on 28 Feb 2024
Minister announces parallel assessment means new medicines assessed sooner
28 February 2024 - PHARMAC is changing its process so it can assess a funding application at the same time Medsafe ...
Posted by Michael Wonder on 27 Feb 2024
Etrasimod arginine for the treatment of patients with moderate to severe active ulcerative colitis
27 February 2024 - NICE has published final evidence-based recommendations on the use of etrasimod arginine (Velsipity) for the treatment ...